Major ABO Incompatibility in Non-Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease-Not an...

Area of Science:

• Hematology
• Pediatric Hematology
• Transplantation Immunology

Background:

• Hematopoietic stem cell transplantation (HSCT) offers a curative treatment for pediatric sickle cell disease (SCD).
• Major ABO blood group incompatibility between recipients and matched sibling donors (MSD) has historically limited donor options.
• Concerns regarding complications like pure red cell aplasia (PRCA) have restricted the use of ABO-incompatible donors.

Purpose of the Study:

• To evaluate the safety and efficacy of HSCT in pediatric SCD patients with major ABO-incompatible MSDs.
• To demonstrate strategies for overcoming ABO incompatibility in HSCT for SCD.
• To discuss expanding the donor pool by including ABO-incompatible sibling donors.

Main Methods:

• Retrospective case review of three pediatric patients with SCD undergoing HSCT with major ABO-incompatible MSDs.
• Detailed analysis of conditioning regimens, GvHD prophylaxis, and ABO titer reduction strategies.
• Monitoring for complications, including PRCA and GvHD.

Main Results:

• Successful HSCT was achieved in all three cases despite major ABO incompatibility.
• No cases of severe PRCA or significant GvHD were observed.
• Effective ABO titer reduction strategies were employed.

Conclusions:

• HSCT with major ABO-incompatible MSDs is a safe and feasible option for pediatric SCD.
• Careful management and specific strategies can mitigate risks associated with ABO incompatibility.
• Expanding donor eligibility to include ABO-incompatible siblings can increase access to curative HSCT for SCD patients.